BPC-157 Research History: Discovery, Key Trials and Regulatory Timeline

This page summarises, in chronological order, what the peer-reviewed literature records about the origin of BPC-157, the studies most often cited in its research history, and the regulatory status described in recent reviews. Every dated claim below is attributed to the publication it comes from. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or an investigational compound.

Origins: a fragment described from gastric juice

Published reviews consistently described BPC 157 as a synthetic pentadecapeptide — a chain of 15 amino acids — corresponding to a partial sequence of a larger protein called body protection compound (BPC), which researchers reported identifying in human gastric juice (PMID 40005999). A 2019 review in Cell and Tissue Research used the same framing, describing the molecule as a gastric pentadecapeptide that was stable in human gastric juice and that had been studied in models of musculoskeletal soft tissue healing (PMID 30915550).

The verified reviews do not assign a single calendar date to the peptide’s “discovery”; instead they describe a body of work that grew out of gastrointestinal cytoprotection research, with the peptide characterised as an agent derived from a naturally occurring gastric protein rather than as a product of a commercial drug-discovery programme (PMID 40005999). A 2025 literature and patent review catalogued the resulting patent filings alongside the published experimental work, indicating that the intellectual-property record developed in parallel with the academic literature (PMID 40005999).

Who the literature credits

Most of the foundational publications came from a research group based in Zagreb, Croatia. Predrag Sikirić and co-authors wrote the 2022 overview of BPC 157 and the central nervous system published in Neural Regeneration Research (PMID 34380875), and the same group authored a 2017 historical essay in Current Pharmaceutical Design that traced gastrointestinal ulceration and cytoprotection research from Hans Selye’s original 1936 paper on stress through later developments in the field (PMID 28641541). That 2017 paper is useful for understanding context: it situated peptide cytoprotection research within an 80-year lineage of stress and ulcer physiology rather than presenting it as a standalone discovery (PMID 28641541).

Chronology of key publications

The laboratory and animal phase

The experimental record that most citations point back to is preclinical. In a 2011 study published in the Journal of Applied Physiology, researchers reported that BPC 157 promoted the outgrowth of tendon fibroblasts from tendon explants, supported cell survival under oxidative stress and increased tendon fibroblast migration in culture (PMID 21030672). That paper is frequently treated as a mechanistic anchor for later musculoskeletal claims because it examined cellular behaviour directly rather than inferring it from whole-animal outcomes (PMID 21030672).

By 2019, a review in Cell and Tissue Research had gathered the accumulated animal work on tendon, ligament, muscle and bone injury models and described the peptide’s reported role in accelerating musculoskeletal soft tissue healing in those models (PMID 30915550). A separate line of investigation addressed the nervous system: the 2022 Neural Regeneration Research review summarised reported findings in central nervous system models and argued for a broader physiological framing of the peptide’s activity (PMID 34380875). Taken together, these two reviews describe a research programme that expanded from gastrointestinal models outward into musculoskeletal and neurological territory (PMID 30915550; PMID 34380875).

The review era: 2025 and 2026

The most consequential shift in the research history was not a new trial but a wave of formal appraisals. A 2025 systematic review in HSS Journal examined the emerging use of BPC-157 in orthopaedic sports medicine and reported that the available literature was dominated by preclinical animal work, with human clinical evidence sparse (PMID 40756949). A 2025 narrative review in Current Reviews in Musculoskeletal Medicine, framed as “Regeneration or Risk?”, set the reported musculoskeletal findings against the absence of controlled human data and against safety and regulatory uncertainty (PMID 40789979).

In the same period, BPC-157 was increasingly discussed as one member of a wider class. A 2025 review in Arthroscopy considered injectable therapeutic peptides as a possible adjunct in regenerative medicine and sports performance and noted the gap between laboratory interest and verified clinical outcomes (PMID 39265666). A 2026 primer in the American Journal of Sports Medicine was written specifically to help orthopaedic and sports medicine physicians answer questions about injectable peptides they were encountering in practice (PMID 41476424), and a 2026 review in International Journal of Molecular Sciences surveyed therapeutic peptides across aesthetic, metabolic and endocrine conditions, covering effects, safety and clinical application (PMID 42123471).

Translational barriers described in the literature

A 2026 review in Pharmaceutics addressed BPC-157 explicitly as an investigational peptide therapeutic and described biopharmaceutical challenges, formulation strategies and translational development barriers standing between the preclinical record and a registered medicine (PMID 42198317). That paper is an important part of the history because it reframes the question from “what did the animal studies show” to “what would formal drug development require” (PMID 42198317).

Reported Safety Signals: What Studies Report

Safety information in the published record is limited by the same evidence gap that limits efficacy claims. The 2025 systematic review in orthopaedic sports medicine reported that the human safety data available for appraisal were minimal relative to the volume of preclinical publications (PMID 40756949). The 2025 narrative review similarly emphasised unresolved risk questions, including the absence of long-term human follow-up, as a central caution (PMID 40789979).

A 2026 review in Sports Medicine compared approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance and discussed the safety consequences of unapproved products being obtained outside regulated supply chains (PMID 41966639). The 2026 Pharmaceutics review added that product quality, stability and characterisation issues are themselves safety-relevant where no registered formulation exists (PMID 42198317).

Regulatory timeline as published

The regulatory record described in the reviews is short and consistent. Reviews published in 2025 reported that BPC-157 had not been approved as a drug product by major regulators and that its use in humans remained investigational (PMID 40789979). The 2026 Sports Medicine review classified BPC-157 among unapproved peptide therapies when contrasting it with peptide drugs that have completed formal approval pathways (PMID 41966639).

The 2026 American Journal of Sports Medicine primer described the regulatory and anti-doping context clinicians should understand when patients raise injectable peptides, including the unapproved status of several widely discussed compounds (PMID 41476424). The 2025 Arthroscopy review made a comparable point for sports settings, noting that regulatory and competitive-eligibility considerations sit alongside the scientific uncertainty (PMID 39265666). The 2026 Pharmaceutics review described the development barriers that would need to be cleared before any approval pathway could realistically conclude (PMID 42198317). Regulatory status varies by country and changes over time; nothing on this page is legal advice.

What the history does and does not establish

Read as a whole, the record shows a peptide described from human gastric juice, developed within a cytoprotection research tradition traced back to Selye’s 1936 work on stress (PMID 28641541), studied extensively in animal and cell models of tendon and soft tissue injury (PMID 21030672; PMID 30915550), extended into nervous system research (PMID 34380875), and then re-examined critically by systematic and narrative reviews that reported a continuing shortage of human trial data (PMID 40756949; PMID 40789979).

The history does not include a completed, published programme of large randomised controlled human trials, and the 2025 and 2026 reviews are explicit that this absence is the defining feature of the current evidence base (PMID 40756949; PMID 41966639). Readers wanting the broader overview of what the peptide is and how it is studied can continue to the BPC-157 learn page on this site.

References

• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Journal of Applied Physiology, 2011)
• “Stress” is 80 Years Old: From Hans Selye Original Paper in 1936 to Recent Advances in GI Ulceration (Current Pharmaceutical Design, 2017)
• Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell and Tissue Research, 2019)
• Pentadecapeptide BPC 157 and the central nervous system (Neural Regeneration Research, 2022)
• Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance? (Arthroscopy, 2025)
• Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review (Pharmaceuticals, 2025)
• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Current Reviews in Musculoskeletal Medicine, 2025)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives (International Journal of Molecular Sciences, 2026)
• BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers (Pharmaceutics, 2026)